Payment overview · 2025
General Payments
$1,255.96
53 reported records · 18 companies
Healthcare provider profile · identity verified
Gretchen Baldwin, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · JACKSONVILLE, FL · NPI 1679817266
Verified facts
What the public records show
CMS Open Payments records show Gretchen Baldwin, PA-C received $1,255.96 in general payments during 2025 across 53 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $212.15 | 16.9% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $185.96 | 14.8% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $165.22 | 13.2% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $121.27 | 9.7% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $106.18 | 8.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.04 | 5.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.84 | 5.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.12 | 4.9% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$50.23 | 4.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.81 | 3.6% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $33.62 | 2.7% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $26.79 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.43 | 1.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.10 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.82 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.96 | 1.4% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $15.52 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.90 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,255.96 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $177.95 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $165.22 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $141.74 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $136.00 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $127.34 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $121.27 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $106.18 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.84 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $58.62 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.06 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $50.23 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $45.81 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $41.80 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.73 | 2 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $33.62 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.92 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 55 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 51 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 84 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 116 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
116 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 21 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
51 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 462 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 136 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 315 | 113 |
| Gabapentin | Gabapentin | 230 | 83 |
| Lisinopril | Lisinopril | 216 | 70 |
| Losartan Potassium | Losartan Potassium | 203 | 80 |
| Omeprazole | Omeprazole | 191 | 84 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 55 |
| Ozempic | Semaglutide | 132 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 127 | 50 |
| Carvedilol | Carvedilol | 123 | 51 |
| Trazodone Hcl | Trazodone Hcl | 120 | 43 |
| Methocarbamol | Methocarbamol | 118 | 57 |
| Montelukast Sodium | Montelukast Sodium | 118 | 54 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 116 | 22 |
| Metformin Hcl | Metformin Hcl | 113 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 44 |
| Potassium Chloride | Potassium Chloride | 94 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 93 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 87 | 43 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 84 | 68 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 84 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 50 |
| Jardiance | Empagliflozin | 84 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 35 |
| Furosemide | Furosemide | 83 | 29 |
| Ezetimibe | Ezetimibe | 77 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 40 |
| Azithromycin | Azithromycin | 75 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 28 |
| Prednisone | Prednisone | 67 | 48 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 66 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 21 |
| Alendronate Sodium | Alendronate Sodium | 63 | 26 |
| Meloxicam | Meloxicam | 63 | 31 |
| Mirtazapine | Mirtazapine | 62 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 24 |
| Linzess | Linaclotide | 59 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 29 |
| Famotidine | Famotidine | 56 | 24 |
| Ondansetron Odt | Ondansetron | 56 | 27 |
| Eliquis | Apixaban | 55 | 21 |
| Chlorthalidone | Chlorthalidone | 54 | 22 |
| Celecoxib | Celecoxib | 53 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 21 |
| Gemtesa | Vibegron | 51 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 21 |
| Methylprednisolone | Methylprednisolone | 49 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 15 |
| Azelastine Hcl | Azelastine Hcl | 46 | 17 |
| Meclizine Hcl | Meclizine Hcl | 45 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 14 |
| Nystatin | Nystatin | 41 | 20 |
| Bupropion Xl | Bupropion Hcl | 40 | 13 |
| Megestrol Acetate | Megestrol Acetate | 40 | 14 |
| Valacyclovir | Valacyclovir Hcl | 39 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 17 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | 15 |
| Tramadol Hcl | Tramadol Hcl | 36 | 15 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 35 | 17 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Allopurinol | Allopurinol | 31 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Baclofen | Baclofen | 31 | 11 |
| Farxiga | Dapagliflozin Propanediol | 31 | 11 |
| Fluconazole | Fluconazole | 31 | 27 |
| Nifedipine Er | Nifedipine | 31 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 28 |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 29 | 17 |
| Alprazolam | Alprazolam | 28 | 13 |
| Metformin Hcl Er | Metformin Hcl | 28 | 13 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | 11 |
| Cyclosporine Modified | Cyclosporine, Modified | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 21 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | 13 |
| Cefdinir | Cefdinir | 21 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Ofloxacin | Ofloxacin | 19 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 14 |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Mupirocin | Mupirocin | 14 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,255.96 · 53 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, Doc Band, ELIQUIS, EVENITY, Extended Holter, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, INJECTAFER, JARDIANCE, Kerendia, MINIMED 780G, MOUNJARO, NURTEC ODT, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, VYNDAMAX, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error